Login to Your Account

Europe still cool on biotech as Txcell gets $22M in scaled-back IPO

By Cormac Sheridan
Staff Writer

Tuesday, April 15, 2014
Cell therapy developer Txcell SA grossed just €16.2 million (US$22.4 million) in a scaled-back initial public offering (IPO) on the Euronext exchange in Paris, evidence that Europe's big funding freeze may be thawing but only gradually.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription